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Acute otitis media, a polymicrobial disease of the middle ear cavity of 17 
children, is a significant public health problem worldwide. It is most 18 
frequently caused by encapsulated Streptococcus pneumoniae and non-19 
typeable Haemophilus influenzae, although the widespread use of 20 
pneumococcal conjugate vaccines is apparently producing an increase in 21 
carriage of non-encapsulated S. pneumoniae. Frequently, pneumococci 22 
and H. influenzae live together in the human nasopharynx forming a self-23 
produced biofilm. Biofilms represent a global medical challenge since the 24 
inherent antibiotic resistance of their producers demands the use of high 25 
doses of antibiotics over prolonged periods. Frequently, these therapeutic 26 
measures fail, contributing to bacterial persistence. Here, we describe the 27 
development of an in vitro, non-encapsulated S. pneumoniae–non-28 
typeable H. influenzae biofilm system using polystyrene or glass-bottom 29 
plates. Using confocal laser scanning microscopy and specific 30 
fluorescent labeling of pneumococcal cells with Helix pomatia agglutinin 31 
revealed an even distribution of both species within the biofilm. This 32 
simple and robust protocol of mixed biofilms has been used for testing 33 
the antimicrobial properties of two well known antioxidants that are widely 34 
used in the clinical setting, i.e., N-acetylcysteine and cysteamine. This 35 
repurposing approach showed the high potency of N-acetylcysteine and 36 
cysteamine against mixed biofilms of non-encapsulated S. pneumoniae 37 
and non-typeable H. influenzae. Decades of clinical use mean that these 38 
compounds are safe to use, which may accelerate their evaluation in 39 
humans. 40 
41 
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Acute otitis media (AOM) is defined as the presence of inflammation in the 42 
middle ear accompanied by the rapid onset of signs and symptoms of an ear 43 
infection. Frequent suppurative complications of AOM are mastoiditis, hearing 44 
loss and meningitis. AOM is a significant public health problem worldwide 45 
(incidence rate ≈11%) (1). Indeed, over 80% of children suffer at least one 46 
episode of AOM by their third birthday, and 40% will suffer six or more 47 
recurrences by the age of 7 years (2). Pediatric AOM, which is often treated 48 
with antibiotics (56–95% of cases depending on the country) (3), represents a 49 
significant healthcare burden, annually accounting for some $2.88 billion in 50 
medical costs in the United States (4). A polymicrobial disease, AOM is typically 51 
caused by colonization of the middle ear space by opportunistic bacteria that 52 
normally form part of the nasopharyngeal microbiota. The most frequently 53 
involved bacterial pathogens are Streptococcus pneumoniae (Sp), non-typeable 54 
(non-encapsulated) Haemophilus influenzae (NTHi), and, to a lesser extent, 55 
Moraxella catarrhalis and other species (5). Several respiratory viruses may 56 
also cause AOM (6). 57 
Pneumococcal conjugate vaccines have significantly reduced the rates of 58 
invasive pneumococcal disease, but their effect on nasopharyngeal colonization 59 
appears to be modest in healthy children and they seem unable to prevent 60 
further episodes (7, 8). The widespread use of pneumococcal conjugate 61 
vaccines, which target the capsular polysaccharide (CPS), has led to decreased 62 
nasopharyngeal carriage of vaccine serotypes, but a concomitant increase in 63 
carriage of non-vaccine serotypes and non-encapsulated S. pneumoniae 64 
(NESp). NESp, which were once considered to be avirulent (with some 65 
exceptions, e.g., those causing conjunctivitis) (9), are currently recognized as 66 
playing important roles in AOM pathogenesis (10). Indeed, NESp accounts for 67 
up to 8% of AOM pneumococcal isolates, the majority resistant to one or more 68 
antibiotics (11), although values near 17% have been reported in some 69 
populations (12). Although the current prevalence of NESp is still a small 70 
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percentage of the pneumococci involved in nasopharyngeal carriage, the 71 
increase in colonization of these strains increases the risk of AOM. 72 
Consequently, NESp that act as a reservoir for antibiotic resistance 73 
determinants may be considered as a newly emerging human pathogen (12, 74 
13). 75 
The term “biofilm” refers to heterogeneous structures comprising different 76 
populations of microorganisms (both single cells and microcolonies of sister 77 
cells) surrounded by a mixture of biopolymers (synthesized largely by the 78 
biofilm-producing microorganisms themselves) that allows their attachment to 79 
inert or organic surfaces (14). The main biopolymer components of the 80 
extracellular matrix are extracellular polysaccharide(s) plus other 81 
macromolecules such as proteins and nucleic acids. NESp has a marked 82 
capacity to form biofilms in vitro since the capsular polysaccharide usually 83 
behaves as an obstacle to biofilm formation (15-18). NTHi isolated from patients 84 
with AOM, cystic fibrosis, or chronic obstructive pulmonary disease (COPD), 85 
have been proposed to form biofilms in vitro and in vivo (19-21), although a 86 
biofilm-specific extracellular polysaccharide had never been described. Indeed, 87 
we have recently shown that NTHi strains are also capable of forming in vitro a 88 
true biofilm matrix composed of a -glucan together with proteins and nucleic 89 
acids (22). 90 
Recent epidemiological data indicate that biofilm communities are important 91 
determinants of bacterial persistence during recurrent and/or chronic diseases 92 
such as AOM (23, 24). One of the characteristics of a biofilm is recalcitrance; 93 
the antibiotic concentrations needed to eradicate biofilm-forming bacteria can 94 
be up to 1000 greater than those required to eliminate planktonic 95 
microorganisms (25). 96 
Polymicrobial infections certainly have a profound impact on the progression 97 
and severity of disease, and the patient's response to treatment. Thus, 98 
knowledge of the mechanisms of polymicrobial biofilm formation may provide 99 
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insight into effective, alternative (or complementary) therapies for AOM. The 100 
present work describes an in vitro, mixed NESp–NTHi biofilm system as a 101 
model for examining the course of polymicrobial infections. Importantly, biofilm-102 
grown NESp and NTHi are shown to be very susceptible to two antioxidant 103 
compounds: N-acetyl-L-cysteine (NAC) and cysteamine (Cys). 104 
MATERIALS AND METHODS 105 
Mixed biofilm formation assay and quantification and susceptibility 106 
testing. The bacterial strains used to produce mixed biofilms were NTHi 54997 107 
and NESp P233. NTHi 54997, isolated from a child with AOM (21), was grown 108 
in brain heart infusion (BHI) supplemented with hemin and NAD (15 μg/ml each) 109 
(sBHI) or on chocolate agar (Conda-Pronadisa). Non-encapsulated S. 110 
pneumoniae P233 — a novobiocin-resistant transformant of the common 111 
laboratory strain R6 using chromosomal DNA from strain M22 (26) — was 112 
incubated in C+Y medium (CpH8 with 0.08% of yeast extract) (27). Biofilm 113 
formation was determined using a modified crystal violet (CV) assay (27). NTHi 114 
was grown at 37 C under 5% CO2 in sBHI medium to an OD550 of 0.5, 115 
sedimented by centrifugation, resuspended in an equal volume of C+Y 116 
supplemented with hemin and NAD (15 μg/ml each) [s(C+Y)] (22), and diluted 117 
10- or 100-fold. NESp P233 was grown at 37 C in C+Y medium to an OD550 of 118 
≈ 0.5, sedimented by centrifugation, resuspended in an equal volume of s(C+Y), 119 
and diluted 10- or 100-fold. The suspensions of NTHi and NESp were mixed in 120 
different proportions and aliquots (200 l final volume) containing 4  106–107 121 
CFU/ml were dispensed into 96-well polystyrene microtitre plates (Costar 3595; 122 
Corning). Biofilm formation proceeded for 2–8 h at 37 C in a 5% CO2 123 
atmosphere. A substantial decrease in NESp viability was observed when 124 
incubation proceeded for more than 8 h (see below). The absorbance at 595 nm 125 
(A595) was determined using a VERSAmax microplate absorbance reader 126 
(Molecular Devices). The quantification of viable cells (planktonic and biofilms 127 
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cells) was performed in blood agar plates containing novobiocin (10 μg/ml) for 128 
NESp, and chocolate agar plates supplemented with 0.16 μg/ml ampicillin for 129 
NTHi. Colonies were counted after overnight incubation at 37 C under 5% CO2. 130 
The susceptibility of planktonic grown NTHi 54997 and NESp P233 to 131 
antibacterial agents was determined using the broth microdilution method 132 
according to CLSI guidelines (28). The MIC values for NAC and Cys were 133 
identical for both strains (2.5 mg mL–1) (data not shown). 134 
Microscopic observation of biofilms and staining with the Helix pomatia 135 
agglutinin HPA. For the observation of mixed biofilms by confocal laser 136 
scanning microscopy (CLSM), biofilms were grown on glass-bottomed dishes 137 
(WillCo-dish, WillCo Wells B. V., The Netherlands) for 5–6 h at 37 C under 5% 138 
CO2. Following incubation, the culture medium was removed and the biofilm 139 
rinsed with sterile water to remove non-adherent bacteria. The biofilms were 140 
then stained with Helix pomatia (edible snail) agglutinin (HPA) conjugated to 141 
Alexa Fluor-488 (2.5–25 μg/ml), the bacterial viability BacLight kit, or SYTO 59; 142 
all staining procedures involved incubation for 10–20 min at room temperature 143 
in the dark. After staining, biofilms were gently rinsed with 0.5 ml phosphate-144 
buffered saline (PBS). Observations were made at a magnification of 63  using 145 
a Leica TCS-SP2-AOBS-UV CLSM equipped with an argon ion laser. Images 146 
were analyzed using LCS software from LEICA. Projections were obtained in 147 
the planes x–y (individual scans at 0.5 μm intervals) and x–z (images at 6 μm 148 
intervals). 149 
Anti-biofilm therapy. NTHi 54997 was grown at 37 C under 5% CO2 in sBHI 150 
medium to an OD550 of ≈ 0.5, sedimented by centrifugation, resuspended in an 151 
equal volume of s(C+Y) and diluted 100-fold. NESp P233 was grown at 37 C in 152 
C+Y medium to an OD550 of ≈ 0.5, sedimented by centrifugation, resuspended 153 
in an equal volume of s(C+Y), and diluted 100-fold. Inocula of 5–7  106 CFU of 154 
each strain were dispensed (in a final volume of 200 μl) into 96-well polystyrene 155 
microtitre plates (Costar 3595; Corning). Biofilm formation proceeded for 5 h at 156 
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37 C under 5% CO2; to remove non-adherent bacteria the planktonic grown 157 
cells were aspirated and the biofilm rinsed with PBS. The resulting biofilms were 158 
washed twice with sterile distilled H2O and then treated for an additional 1 h at 159 
37 C in a 5% CO2 atmosphere with various concentrations of NAC or Cys. 160 
Controls were run without antioxidants. The biofilms were then washed twice 161 
with sterile distilled H2O, disaggregated by gentle pipetting and slow vortexing 162 
(29), and a 10-fold dilution series prepared in PBS. Viability was assessed by 163 
plate counting as indicated above. 164 
RESULTS 165 
Inoculum size and length of incubation are important factors in the 166 
development of mixed biofilms. Using an NESp strain that produces fairly 167 
large amounts of biofilms in vitro (15-18) and a modified culture medium, the 168 
present work examined the influence of initial cell concentrations on 169 
pneumococcal and NTHi survival (Fig. 1). Using NTHi 54997 (a large amount 170 
biofilm-producer) (21) and the NESp P233, different bacterial proportions (from 171 
1:40 to 10:1 NESp:NTHi) were tested at an overall initial bacterial density of 4  172 
106–107 CFU/ml. No major differences were seen in biofilm formation (after 6 h 173 
incubation at 37 C under 5% CO2) for the different bacterial proportions over the 174 
1:40–1:1 range. However, after 6 h incubation, the NeSp population in the 175 
mixed biofilms (and also the biofilm formation itself) appeared to decrease when 176 
the initial proportion NESp:NTHi was >1 (Fig. 1), possibly due to the rapid 177 
autolysis characteristic of pneumococci when reaching the stationary phase of 178 
growth. In all further experiments, an NESp:NTHi proportion of  1:1 was used 179 
since this was seen to allow optimal biofilm formation with equally sized 180 
populations of both species maintained (Fig. 1). Under optimal conditions, these 181 
mixed biofilms contain 2  108–3  108 CFU/ml (or 4  107–6  107 CFU/well 182 
[200 l], which corresponds to 2.5  107–3.8  107 CFU/cm2). Biofilm formation 183 
was followed for 8 h after inoculation into s(C+Y) medium (Fig. 2). The NESp–184 
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NTHi mixed biofilms grew at rates similar to those of monospecific biofilms. 185 
Maximum mixed biofilm formation — determined both by CV staining and plate 186 
counting — was obtained after 6 h incubation (Fig. 2C and D). Notably, the 187 
adhesion of Sp to the walls of the well proceeded more rapidly than that of 188 
NTHi, but the number of attached bacteria of both species equalized after 4 h 189 
incubation (Fig. 2D). After 6 h of incubation, about 35% and 45% of the NESp 190 
and NTHi total cells respectively were adhered. At 8 h post-inoculation, the 191 
viability of Sp declined, probably through autolysis-dependent death (27). 192 
Spatial distribution of bacteria in NESp+NTHi mixed biofilms. Lectins are 193 
a large group of proteins often used as probes for locating carbohydrates in 194 
cells and tissues. After evaluating a lectin panel, it was found that HPA 195 
conjugated to Alexa Fluor-488 was capable of strongly binding to the surface of 196 
NESp cells (Fig. 3B), but not to that of NTHi cells (Fig. 3E). Pneumococci were 197 
seen to be homogeneously distributed throughout the biofilm and among the 198 
NTHi cells (Fig. 3I). It should be noted, however, that HPA labeling is not 199 
exclusive to Sp cells and that this lectin may also be useful in the identification 200 
and localization of other bacteria (unpublished results). 201 
Bactericidal effect of NAC and Cys in mixed biofilms. Under the present 202 
experimental conditions, mixed biofilms exposed to 0.1 mg/ml NAC for 1 h 203 
showed the death of <10% of NESp but ≈99% of NTHi. At 0.5 mg/ml, NAC killed 204 
99% of NESp and practically eliminated NTHi. At 2.5 mg/ml (the MIC for 205 
planktonic cultures) bacteria were virtually eradicated (Fig. 4A). Cys caused a 206 
90% reduction in viability in both pathogens when used at 0.5 and 2.5 mg/ml 207 
(Fig. 4B). A concentration of 5 mg/ml led to the almost total killing of NTHi and 208 
to the survival of just 2% of NESp cells (Fig. 4B). In agreement with viable 209 
counts, CLSM images showed the intense lethal effect of 0.5 mg/ml NAC on the 210 
mixed biofilm (Fig. 5); a partial disintegration of the biofilm could also be 211 
observed. It should be noted that at concentrations of ≥2.5 mg/ml, most cells in 212 
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the biofilm stained green (data not shown), although they were non-viable as 213 
deduced since they produced no colonies in agar plating experiments. This 214 
finding is an additional drawback to those previously reported for the BacLight 215 
viability kit (30). 216 
DISCUSSION 217 
Microbial biofilms contribute to the establishment of chronic infections by 218 
conferring increased antibiotic resistance to the bacteria within them, and by 219 
helping them circumvent host defenses (29). S. pneumoniae and NTHi are 220 
nasopharyngeal commensals associated with many common respiratory tract 221 
infections. Several known virulence factors produced by these pathogens have 222 
been associated with their ability to form biofilms, e.g., the CPS, several surface 223 
proteins, the neuraminidases NanA and NanB, or various quorum sensing 224 
systems (15, 16, 18, 31, 32). Interestingly, recent experimental evidence has 225 
shown that some NESp lack several common surface proteins expressed by 226 
encapsulated pneumococci (e.g., the choline-binding proteins PspA, PspC, and 227 
PcpA), but express an specific virulence factor PspK (an LPxTG binding 228 
protein), which has been shown to increase NESp colonization and virulence 229 
during AOM (for a review, see reference 11). However, few studies have 230 
examined the influence of mixed Sp–NTHi biofilm formation in vitro. A recent 231 
report showed cell density-dependent interaction between encapsulated S. 232 
pneumoniae and NTHi in mixed in vitro biofilms: high initial cell densities of Sp 233 
(106 CFU/ml) were reported to inhibit NTHi growth, whereas high cell densities 234 
of NTHi (106 CFU/ml) enhanced Sp survival after 24 h incubation when Sp was 235 
initially present in lower densities (104 CFU/ml) (33). According to the authors, 236 
the increased survival of Sp might be explained, at least in part, by NTHi-237 
induced downregulation of the pneumococcal genes lytA and cbpD, which are 238 
known to be involved in autolysis and death. 239 
10 
 
In the present work, an in vitro NESp–NTHi mixed biofilm system was 240 
established which showed that, during the early stages of co-infection, NESp 241 
precedes NTHi in adhering to a substrate and thus initiating biofilm formation. 242 
However, both populations were equal in number when the biofilm was mature. 243 
Whether this behavior is related to the observation that pneumococci are more 244 
frequently responsible for early episodes of AOM (34) remains to be 245 
determined. 246 
Identifying the different species within a polymicrobial biofilm is no easy task, 247 
but an understanding of the micron-scale spatial organization of bacterial 248 
communities is essential if we are to understand how they function. 249 
Fluorescence in situ hybridization (FISH) is a well-established means of 250 
visualizing and identifying microbial species in natural and artificially created 251 
multispecies biofilms (35). However, FISH requires chemical 252 
fixation/permeabilization of the cells plus subsequent hybridization, which 253 
usually takes a few hours to complete. Cells thus fixed are no longer viable; 254 
indeed, we have noticed chemically-fixed monospecific biofilms to show altered 255 
morphology under CLSM examination (unpublished observations). Live-cell 256 
imaging using strains showing fluorescence or bioluminescence have been 257 
proposed as alternatives to FISH. For example, highly fluorescent Sp have 258 
been constructed using a superfolder green fluorescent GFP as a protein 259 
reporter (36). Nevertheless, when we have used these constructs for producing 260 
NESp and NESp–NTHi in vitro biofilms, significant differences in fluorescence 261 
were noted among individual bacteria (unpublished observations). In the 262 
present study, however, fluorescent staining of NESp with the HPA lectin 263 
allowed to reveal that the NESp cells were evenly distributed throughout the 264 
biofilm and interspersed with NTHi. HPA specifically recognizes terminal -N-265 
acetyl-D-galactosamine ( GalNAc) residues (37) suggesting that this lectin 266 
binds to the Forssman cross-reactive material of Sp, this is, the lipoteichoic acid 267 
(38). 268 
11 
 
There is an urgent need for alternatives (or complements) to antibiotics, 269 
particularly for treating infections involving biofilms. Certainly, growth in a 270 
polymicrobial biofilm increases resistance to antibiotics (39). Different strategies 271 
have been developed for preventing and/or treating biofilm-related infections, 272 
such as the use of enzymes that degrade the biofilm matrix, inhibitors of 273 
quorum-sensing signals, anticoagulant agents, surfactants, and specific 274 
bacteriophages or their endolysins (40-42). In the present study, the mucolytic 275 
compounds NAC and Cys were examined to determine whether these drugs 276 
might have a future in the management of AOM caused by NESp–NTHi mixed 277 
biofilms. A limitation of the present study, however, is that only a single strain of 278 
each bacterial species has been used and it is possible that other strains may 279 
behave differently. NAC is a potent thiol-containing antioxidant which serves as 280 
a precursor of glutathione synthesis and is used in the treatment of many 281 
diseases (43). Moreover, NAC efficiently reduces disulphide bonds in proteins, 282 
and alters their structure, leading to a reduction in the viscosity of secretions 283 
and to the inhibition/inactivation of the proteins involved in biofilm syntesis and 284 
maintenance. This hinders bacterial adherence and biofilm formation by a 285 
variety of bacteria (44). Cys is also an antioxidant, licensed for use in 286 
nephropathic cystinosis (45). It has also been proposed suitable for use in 287 
Huntington’s and Parkinson’s diseases, malaria, neuropsychiatric disorders (46) 288 
and cystic fibrosis (CF) (47-49). Cys also prevents the formation of, and disrupts 289 
already established, P. aeruginosa and Enterococcus faecalis biofilms (47, 50). 290 
NAC and Cys show antimicrobial activity against Gram-positive and Gram-291 
negative pathogens with MICs usually falling in the range 500–5000 g/ml (47, 292 
48, 51-53), although lower values have been reported for some bacteria (48, 293 
54). It is generally recognized that the mechanisms underlying the therapeutic 294 
and clinical applications of NAC (and Cys) are still unclear and, possibly, more 295 
complex than previously envisaged (55). However, it has recently been 296 
proposed that the antimicrobial activity of NAC could be related to: 1) 297 
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competitive inhibition of cysteine utilization; 2) reaction of the NAC sulfhydryl 298 
group with bacterial proteins; and/or 3) perturbation of the intracellular redox 299 
equilibrium with potential indirect effects on cell metabolism and intracellular 300 
signal transduction pathways (56). Nevertheless, additional studies are 301 
warranted to provide a definite answer to this question. To the best of our 302 
knowledge, the isolation of bacteria resistant (or tolerant) to NAC/Cys has not 303 
been reported. However, their potential emergence should be kept under 304 
surveillance. 305 
Although it has been reported that only reduced peak plasma concentrations 306 
(0.35–4 g/ml) are achieved after a single oral dose (200–400 mg) of NAC (57), 307 
the concentrations of NAC that killed NESp–NTHi cells forming the present in 308 
vitro biofilms are close to those that can theoretically be obtained in 309 
oropharyngeal secretions when a normal dose of oral NAC medication is 310 
administered (usually ranging from 200–600 mg in tablets taken 2 or 3 times 311 
daily) (58). Moreover, various modified intravenous NAC protocols have also 312 
been developed and peak plasma concentrations of 0.2–1.2 mg/ml have been 313 
reported depending on the protocol (for a review, see reference (59)). These 314 
values are of the same order of magnitude than those killing mixed biofilms in 315 
the present in vitro study (0.1–2.5 mg/ml). NAC can also be administered 316 
directly into the middle ear; transtympanic injections of up to 20 mg/ml NAC also 317 
appear to be well tolerated in humans (60, 61). In addition, several clinical 318 
studies have been recently performed to explore the efficacy of NAC in COPD 319 
with encouraging results, especially when the drug was administered at high-320 
doses (1200 mg/day on average) for a long period of time (up to one year) (62). 321 
Interestingly, although a role of biofilms in patients with COPD has not been 322 
directly demonstrated, it is well known that the airways of these patients are 323 
frequently colonized by pathogens such as Hi and Sp. 324 
As the development of new drugs becomes increasingly expensive, drug 325 
repurposing (or reprofiling) has enjoyed unexpected success and has been 326 
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adopted as a priority by the National Institutes of Health (63). The reprofiling of 327 
FDA-approved peptide drugs and antimicrobial peptides in clinical development 328 
as possible anti-biofilm drugs is currently being investigated (64). On the basis 329 
of the present results, NAC and Cys warrant further research as repurposed 330 
drugs for the treatment of AOM caused by NESp–NTHi mixed biofilms. 331 
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FIGURE LEGENDS 551 
FIG 1 Influence of bacterial proportions on NESp–NTHi mixed biofilm formation 552 
in vitro. Exponentially growing cultures of NESp P233 and NTHi 54997 in 553 
s(C+Y) medium were diluted to ≈ 5  106 CFU/ml and mixed in different 554 
proportions (NESp:NTHi; 1:40, 1:15, 1:3, 1:2, 1:1, 3:1 and 10:1). Two hundred 555 
l of the mixture were then distributed into the wells of a polystyrene microtitre 556 
plate and incubated for 6 h at 37 C under 5% CO2. (A) The viability of NESp 557 
(squares) and NTHi (circles) was determined by plate counting. (B) Grey bars 558 
indicate mixed biofilm formation determined by CV staining. The initial 559 
NESp:NTHi proportions are shown inside the bars. Data represent the average 560 
of three experiments. Standard error bars are shown. 561 
FIG 2 Time course of NESp–NTHi mixed biofilm formation. Exponentially 562 
growing cultures of NESp P233 and NTHi 54997 in s(C+Y) medium were 563 
diluted in the same medium to ≈ 106 CFU/ml and mixed in a 1:1 proportion. Two 564 
hundred l were then distributed into the wells of a polystyrene microtitre plate 565 
and incubation allowed at 37 C in a 5% CO2 atmosphere. At the indicated 566 
times, plate counting was performed. (A) Biofilm formation by NESp. (B) Biofilm 567 
formation by NTHi. (C, D) Mixed biofilms. Open, blackened, and grey bars 568 
correspond, respectively, to the non-adherent cells of the biofilm and to biofilm-569 
grown cells of NESp and NTHi. Crosshatched and hatched bars indicate 570 
bacterial growth and biofilm formation in mixed cultures respectively. The data 571 
represent the average of six experiments. 572 
FIG 3 S. pneumoniae labelling in mixed biofilms with HPA. Biofilms formed by 573 
NESp P233 (A–C), NTHi 54997 (D–F) or both (G–I) were stained with a 574 
combination of SYTO 9 (green) and HPA conjugated to Alexa Fluor-488 (pink). 575 
Projections were obtained in the planes x–y (individual scans at 0.5 μm 576 
intervals) and x–z (images at 6 μm intervals). Scale bars = 25 m. 577 
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FIG 4 Killing of S. pneumoniae P233 and NTHi 54997 in mixed biofilms with 578 
antioxidants. Mixed biofilms were washed with sterile distilled H2O and 579 
incubated with different concentrations of NAC (A) or Cys (B) for 1 h at 37 C in 580 
a 5% CO2 atmosphere. Blackened and grey bars correspond to NESp and NTHi 581 
viability respectively. Data represent the average of five experiments. 582 
FIG 5 CLSM of a mixed biofilm after exposure to NAC. An NESp–NTHi biofilm 583 
was let untreated (A) or was treated with 0.5 mg/ml NAC for 1 h at 37 C under 584 
5% CO2 (B). The cells in the biofilms were then stained with the BacLight 585 
LIVE/DEAD kit to reveal viable (green fluorescence) and non-viable (red 586 
fluorescence) bacteria. In all images the scale bar is 25 μm. 587 
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